# Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)

> **NCT02368691** · PHASE2 · TERMINATED · sponsor: **GTx** · enrollment: 32 (actual)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** GTx-024

## Key facts

- **NCT ID:** NCT02368691
- **Lead sponsor:** GTx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-06
- **Primary completion:** 2017-09-22
- **Final completion:** 2017-09-22
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** Lack of Efficacy
- **Last updated:** 2020-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02368691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02368691, "Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02368691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*